We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

78 hedge funds and large institutions have $185M invested in BioSpecifics Technologies Corp. in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $176M → $185M (+$9.37M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

10% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 31

11% less funds holding

Funds holding: 8878 (-10)

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

Holders
78
Holders Change
-10
Holders Change %
-11.36%
% of All Funds
1.79%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
8
Increased
28
Reduced
31
Closed
17
Calls
Puts
Net Calls
Net Calls Change

BSTC Hedge Fund Activity: Q1 2018 in Review

78 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q1 2018, worth a combined $185M — up 5.3% from $176M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of BSTC and 8 opened new positions — a net loss of 9 holders — while 31 trimmed existing stakes and 28 added.

The largest buyer was Stonepine Capital Management, adding an estimated $8.57M. The largest seller was Northpointe Capital, exiting entirely with an estimated $3.5M sold.

  • 78 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q1 2018, down from 88 in Q4 2017.
  • Funds reported $185M of BioSpecifics Technologies Corp. stock for Q1 2018, up 5.3% quarter-over-quarter.
  • 8 funds opened new BioSpecifics Technologies Corp. positions in Q1 2018 and 17 closed out, a net change of -9 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q1 2018 was Stonepine Capital Management, an estimated $8.57M added.
  • The largest BioSpecifics Technologies Corp. seller in Q1 2018 was Northpointe Capital, an estimated $3.5M sold.

Based on aggregated 13F filings for Q1 2018.